Drug developers are sharpening their focus on machine learning (ML) — exploring the use of algorithms to sift through massive volumes of molecular, biochemical and genomic data. “AI is contributing to the acceleration of the discovery and development of new drugs and will continue to have a significant impact in 2023,” said Sigma Mostafa, senior vice president and site head at KBI Biopharma.
“As ML continues to become more accessibl…